



InnovFin Infectious Diseases

A new Finance Facility to stimulate investment in Infectious Disease R&D

Patricia Paukovits

Unit for Fighting infectious diseases and advancing public health
Health Directorate, DG RTD

A New Financial Instrument for Infectious Diseases R&D

- Jointly developed by the European Commission and European Investment Bank.
- Established under InnovFin - EU Finance for Innovators*
- Provides loans between EUR 7.5m and EUR 75m to innovative players active in developing **vaccines**, **drugs**, medical and diagnostic **devices**, and research **infrastructures** for combatting infectious diseases.
- Launched 15 June 2015 in Riga during 'The First Innovative Enterprise Week'.

*<http://www.eib.org/products/blending/innovfin/>



InnovFin ID – Policy Aims

- Support EC President Jean Claude Juncker's agenda for Jobs, Growth, Fairness and Democratic Change and his investment plan, which includes the creation of a European Fund for Strategic Investment (EFSI)
- Contribute to the post-2015 development agenda and key components of Global Partnership for Poverty Eradication and Sustainable Development
- Contribute to effective use of public finance and mobilise the private sector with the aim of eradicating poverty and achieving inclusive and sustainable development.
- Contribute to Europe's leadership in addressing global challenges.
- Ensure that new drugs, vaccines and medical and diagnostic devices are made available faster to people who need them.



Why target Infectious Diseases?

Infectious Diseases (IDs) pose a major global health threat

2nd leading cause of mortality: approximately **17% of all deaths globally**

Uncertain ID market perspective deters investment

- The highest burden is in low- and middle-income regions with the lowest purchasing power
- ID treatments for emerging epidemics may never be deployed and provide no incentive for investment
- ID treatments are jeopardised by antimicrobial resistance, and the main countermeasure – restricted use – discourages drug developers to invest in this area
- **The support for the fight against infectious diseases constitutes a key public health priority for the European Union**



1st Example

CaVIDI

- €10 million loan from EIB, backed by H2020
- Low-cost HIV viral load testing device was proven to work in simplified, less sophisticated laboratories, in FP7 EU project
- Loan will allow CavidI to develop an automated, high-throughput version of the device, and launch it in January 2016.



Impact of InnovFin ID

- Increase of EU investments in ID research
- Redeployment of funds: reflows allow financing of a significantly higher volume of projects through several financing rounds.
- InnovFin ID is expected to generate a MULTIPLIER of about 9x the initial contribution.
- De-risking of investments and encouraging more investment in this area.
- Enabling further roll-out to the market of new drugs, vaccines, diagnostics and medical technologies to combat ID.
- Fostering of healthcare sector and hence creating jobs and growth in the EU.
- Strengthen capacity to deliver new medical products to people who need them.

→ Getting much more for less!





Application & inquiries directly with the EIB:
innovfinIDFF@eib.org

Further Information:

- **www.eib.org/innovfin**
- **http://www.eib.org/attachments/documents/innovfin_infectious_diseases_flysheet_en.pdf**

Contacts at the European Commission, DG RTD, Unit for Fighting Infectious Diseases and Advancing Public Health:

Line Matthiessen, Line.MATTHIESSEN@ec.europa.eu

Patricia Paukovits, Patricia.PAUKOVITS@ec.europa.eu

